

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### HealthTech Programme

#### Blood-based biomarker tests for surveillance in people at risk of hepatocellular carcinoma (HTG10175)

#### Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit, appeal or raise a resolution request)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Abbott</li> <li>• Roche Diagnostics</li> <li>• Fujifilm</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• AIH Support</li> <li>• ADFAM</li> <li>• Alcohol Change UK</li> <li>• akt</li> <li>• British Liver Trust</li> <li>• Cancer 52</li> <li>• Cancer Black Care</li> <li>• Centrepont</li> <li>• Compass UK</li> <li>• Crisis</li> <li>• Emmaus UK</li> <li>• Foundation for Liver Research</li> <li>• Groundswell</li> <li>• Guts UK</li> <li>• Help The Homeless</li> <li>• Homeless Connect</li> <li>• Homeless Link</li> <li>• Haemochromatosis UK</li> <li>• Independent Cancer Patients Voice</li> <li>• Liver4Life</li> <li>• LIVErNORTH</li> <li>• Macmillan Cancer Support</li> <li>• Maggies Centres</li> <li>• Marie Curie</li> <li>• PBC Foundation</li> <li>• Pelican Cancer Foundation</li> <li>• Primary Sclerosing Cholangitis Support (PSC Support)</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Association of British Healthcare Industries (ABHI)</li> <li>• Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)</li> <li>• Board of Community Health Councils in Wales</li> <li>• British In Vitro Diagnostics Association</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health - Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Health Technology Wales</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Confederation</li> <li>• NHS Wales Joint Commissioning Committee</li> <li>• Scottish Medicines Consortium</li> <li>• UK NEQAS</li> <li>• Welsh Government</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cancer Research UK</li> <li>• Genomics England</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> </ul>

Provisional stakeholder list for the evaluation of Blood-based biomarker tests for surveillance in people at risk of hepatocellular carcinoma (HTG10175)

Issue date: June 2026

© National Institute for Health and Care Excellence 2026. All rights reserved.

1 of 4

Provisional Consultees	Provisional Commentators (no right to submit, appeal or raise a resolution request)
<ul style="list-style-type: none"> <li>• Royal Victoria Hospital Liver Support Group</li> <li>• Sharan</li> <li>• Shelter</li> <li>• Simon Community Northern Ireland</li> <li>• St Mungo's</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus Cancer Care</li> <li>• The Hepatitis B Trust</li> <li>• The Hepatitis C Trust</li> <li>• Wilson's Disease Support Group UK</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• Association for Clinical Biochemistry and Laboratory Medicine</li> <li>• British Association for the Study of the Liver</li> <li>• British Geriatrics Society</li> <li>• British Medical Association</li> <li>• British Medical Ultrasound Society</li> <li>• British Society of Gastrointestinal and Abdominal Radiology</li> <li>• British Society of Gastroenterology</li> <li>• British Liver Nurses' Association</li> <li>• Nursing and Midwifery Council</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Physicians and Surgeons of Glasgow</li> <li>• Royal College of Radiologist</li> <li>• Royal College of Surgeons of Edinburgh</li> <li>• Royal College of Surgeons of England</li> <li>• Royal Society of Medicine</li> <li>• Welsh Cancer Network</li> <li>• Welsh Association Gastroenterology and Endoscopy</li> <li>• UK Oncology Nursing Society</li> </ul>	<ul style="list-style-type: none"> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul> <p><u>External Assessment Group</u></p> <ul style="list-style-type: none"> <li>• York Health Economics Consortium (YHEC)</li> </ul>

Provisional stakeholder list for the evaluation of Blood-based biomarker tests for surveillance in people at risk of hepatocellular carcinoma (HTG10175)

Issue date: June 2026

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit, appeal or raise a resolution request)</b>
<u>Others</u> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal or raise a resolution request against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal or raise a resolution request against the Final Draft Guidance (FDG).

The process and methods that NICE will follow for the assessment process, after scoping, will depend on the assessment type. It will follow either the [NICE technology appraisal and highly specialised technologies guidance: the manual](#) if the assessment type is via the National HealthTech Access Programme, otherwise it will follow the NICE HealthTech programme manual. The case of the former, the aforementioned consultees will be able to appeal the final draft guidance and in case of the latter, they would be able to raise a resolution request.

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations

Provisional stakeholder list for the evaluation of Blood-based biomarker tests for surveillance in people at risk of hepatocellular carcinoma (HTG10175)  
 Issue date: June 2026

and they receive the FDG for information only, without the right to appeal or raise a resolution request. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.